The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D
Notice of Exempt Offering of Securities

1. Issuer's Identity

<table>
<thead>
<tr>
<th>CIK (Filer ID Number)</th>
<th>Previous Names</th>
<th>Entity Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001461993</td>
<td>None</td>
<td>X Corporation</td>
</tr>
</tbody>
</table>

Name of Issuer: MELINTA THERAPEUTICS, INC. /NEW/

Jurisdiction of Incorporation/Organization: DELAWARE

Year of Incorporation/Organization: X Over Five Years Ago

2. Principal Place of Business and Contact Information

Name of Issuer: MELINTA THERAPEUTICS, INC. /NEW/

Street Address 1: 300 GEORGE STREET

City: NEW HAVEN

State/Province/Country: CONNECTICUT

ZIP/PostalCode: 06511

Phone Number of Issuer: 312 767 0291

3. Related Persons

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wechsler</td>
<td>Daniel</td>
<td></td>
</tr>
<tr>
<td>Galeota, J.</td>
<td>Jay</td>
<td>J.</td>
</tr>
<tr>
<td>Gill</td>
<td>David</td>
<td></td>
</tr>
</tbody>
</table>

Relationship: X Executive Officer X Director

Clarification of Response (if Necessary):

Director, President and Chief Executive Officer

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wechsler</td>
<td>Daniel</td>
<td></td>
</tr>
<tr>
<td>Galeota, J.</td>
<td>Jay</td>
<td>J.</td>
</tr>
<tr>
<td>Gill</td>
<td>David</td>
<td></td>
</tr>
</tbody>
</table>

Relationship: X Executive Officer X Director

Clarification of Response (if Necessary):
<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
<th>Street Address 1</th>
<th>Street Address 2</th>
<th>City</th>
<th>State/Province/Country</th>
<th>ZIP/PostalCode</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gonzalo</td>
<td>Cecilia</td>
<td></td>
<td>300 George Street, Suite 301</td>
<td></td>
<td>New Haven</td>
<td>CONNECTICUT</td>
<td>06511</td>
</tr>
<tr>
<td>Johnson</td>
<td>John</td>
<td>H.</td>
<td>300 George Street, Suite 301</td>
<td></td>
<td>New Haven</td>
<td>CONNECTICUT</td>
<td>06511</td>
</tr>
<tr>
<td>Koestler</td>
<td>Thomas</td>
<td>P.</td>
<td>300 George Street, Suite 301</td>
<td></td>
<td>New Haven</td>
<td>CONNECTICUT</td>
<td>06511</td>
</tr>
<tr>
<td>Kong</td>
<td>Garheng</td>
<td></td>
<td>300 George Street, Suite 301</td>
<td></td>
<td>New Haven</td>
<td>CONNECTICUT</td>
<td>06511</td>
</tr>
<tr>
<td>Zaccardelli</td>
<td>David</td>
<td></td>
<td>300 George Street, Suite 301</td>
<td></td>
<td>New Haven</td>
<td>CONNECTICUT</td>
<td>06511</td>
</tr>
<tr>
<td>Ferro</td>
<td>Kevin</td>
<td>T.</td>
<td>300 George Street, Suite 301</td>
<td></td>
<td>New Haven</td>
<td>CONNECTICUT</td>
<td>06511</td>
</tr>
</tbody>
</table>
4. Industry Group
Agriculture

Banking & Financial Services
  
  Commercial Banking
  
  Insurance
  
  Investing
  
  Investment Banking
  
  Pooled Investment Fund

Is the issuer registered as an investment company under the Investment Company Act of 1940?

Yes [ ]
No [ ]

Other Banking & Financial Services

Business Services
  
  Energy
    
    Coal Mining
    
    Electric Utilities
    
    Energy Conservation
    
    Environmental Services
    
    Oil & Gas
    
    Other Energy

Health Care
  
  Biotechnology
  
  Health Insurance
  
  Hospitals & Physicians

Pharmaceuticals [ ]

Other Health Care

Manufacturing

Real Estate
  
  Commercial
  
  Construction

REITS & Finance

Residential

Other Real Estate

Other Travel

Technology

Computers [ ]

Telecommunications [ ]

Other Technology [ ]

Travel

Airlines & Airports [ ]

Lodging & Conventions [ ]

Tourism & Travel Services [ ]

Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range

No Revenues [ ] $1 - $5,000,000

$1,000,001 - $5,000,000 [ ] $5,000,001 - $25,000,000

$25,000,001 - $50,000,000 [ ] $50,000,001 - $100,000,000

Over $100,000,000 [ ] Over $100,000,000

Decline to Disclose [ ] Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii)) [ ]

Rule 504 (b)(1)(i) [ ]

Rule 504 (b)(1)(ii) [ ]

Rule 504 (b)(1)(iii) [ ]

Rule 505 [ ]

Rule 506(b) [ ]

Rule 506(c) [ ]

Securities Act Section 4(a)(5) [ ]

Investment Company Act Section 3(c) [ ]

Section 3(c)(1) [ ]

Section 3(c)(2) [ ]

Section 3(c)(3) [ ]

Section 3(c)(4) [ ]

Section 3(c)(5) [ ]

Section 3(c)(6) [ ]

Section 3(c)(7) [ ]

Section 3(c)(9) [ ]

Section 3(c)(10) [ ]

Section 3(c)(11) [ ]

Section 3(c)(12) [ ]

Section 3(c)(13) [ ]

Section 3(c)(14) [ ]

7. Type of Filing

X New Notice Date of First Sale 2018-01-05

First Sale Yet to Occur
8. Duration of Offering

Does the Issuer intend this offering to last more than one year?  
☐ Yes  ☑ No

9. Type(s) of Securities Offered (select all that apply)

- ☑ Equity
- ☑ Pooled Investment Fund Interests
- ☑ Debt
- ☑ Tenant-in-Common Securities
- ☑ Option, Warrant or Other Right to Acquire Another Security
- ☑ Mineral Property Securities
- ☑ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
- ☑ Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?  
☐ Yes  ☑ No

Clarification of Response (if Necessary):

In connection with the Issuer's acquisition of the capital stock of certain subsidiaries of The Medicines Company and certain assets related to The Medicines Company's infectious disease business.

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient  
Recipient CRD Number ☑ None

(Associated) Broker or Dealer  
(Associated) Broker or Dealer CRD Number ☑ None

Street Address 1
City
State/Province/Country
ZIP/Postal Code

State(s) of Solicitation (select all that apply)  
☒ All States  ☐ Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount $137,781,477 USD  ☑ Indefinite
Total Amount Sold $137,781,477 USD
Total Remaining to be Sold $0 USD  ☑ Indefinite

Clarification of Response (if Necessary):

Amount sold includes shares given in consideration for an acquisition of stock of subsidiaries and assets of The Medicines Company.

14. Investors

☐ Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering:

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

9

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $0 USD ☑ Estimate
Finders' Fees $0 USD ☑ Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:
  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

<table>
<thead>
<tr>
<th>Issuer</th>
<th>Signature</th>
<th>Name of Signer</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELINTA THERAPEUTICS, INC. /NEW/</td>
<td>Paul Estrem</td>
<td>Paul Estrem</td>
<td>See Clarification Box in Item # 3</td>
<td>2018-01-19</td>
</tr>
</tbody>
</table>

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.